Skip to Content
Merck
  • What's the role of topiramate in the management of patients with hyperkinetic movement disorders?

What's the role of topiramate in the management of patients with hyperkinetic movement disorders?

Pharmacological reports : PR (2012-05-15)
Antonio Siniscalchi, Luca Gallelli, Chiara Giofrè, Giovambattista De Sarro
ABSTRACT

Topiramate (TPM) is an O-alkyl sulfamate derivative of the naturally occurring monosaccharide D-fructose with an epileptic activity. However, it has been suggested that, in addition to its use in epilepsy, TPM could also be used in the treatment of neurological disorders, psychiatric conditions and hyperkinetic movement disorders. The clinical applications of TPM in hyperkinetic movement disorders is consistent with the multiple pharmacodynamic mechanisms e.g., the modulation of both γ-aminobutyric acidergic or glutamatergic neurotransmission and the modulation of voltage-gated ion channels or intracellular signalling pathways. The purpose of the present review is to describe the mechanisms of action of TPM and its clinical efficacy in patients with hyperkinetic movement disorders.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Topiramate, ≥98% (HPLC), solid
USP
Topiramate, United States Pharmacopeia (USP) Reference Standard
Supelco
Topiramate solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®